NICE IDs

09/09/2020

ID1599: Nintedanib for treating progressive fibrosing interstitial lung disease

07/09/2020

ID1592: Ranibizumab for treating diabetic retinopathy

07/09/2020

ID901: Non-bisphosphonates for treating osteoporosis

07/09/2020

ID1672: Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease

07/09/2020

ID1185: Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura

07/09/2020

ID3808: Remdesivir for treating COVID-19

04/09/2020

ID1549: Givosiran for treating acute hepatic porphyria

28/08/2020

ID1412: Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer

28/08/2020

ID1477: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

21/08/2020

ID1326: Volanesorsen for treating familial chylomicronaemia syndrome

21/08/2020

ID1304: Siponimod for treating secondary progressive multiple sclerosis

12/08/2020

ID1591: Belimumab for treating active autoantibody-positive systemic lupus erythematosus

12/08/2020

ID1530: Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS)

09/07/2020

ID1468: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

09/07/2020

ID1586: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

09/07/2020

ID1510: Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable

08/07/2020

ID1473: Onasemnogene abeparvovec for treating spinal muscular atrophy type 1

08/07/2020

ID1294: Ozanimod for treating relapsing-remitting multiple sclerosis

08/07/2020

ID1534: Apalutamide for treating prostate cancer

08/07/2020

ID1420: Nintedanib for treating interstitial lung disease caused by systemic sclerosis